PACIFIC BIOSCIENCES OF CALIFORNIA, INC.

PACIFIC BIOSCIENCES OF CALIFORNIA, INC. has been granted 304 US utility patents between 2015 and 2025, placing PACIFIC BIOSCIENCES OF CALIFORNIA, INC. at rank #1,381 across all assignees tracked by PlainPatent. This portfolio spans 46 distinct Cooperative Patent Classification (CPC) subclasses, averaging 20.4 claims per patent with primary concentration in C12Q (MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS ; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICR). As a US Corporation, PACIFIC BIOSCIENCES OF CALIFORNIA, INC. is one of the more focused assignees in the PatentsView dataset. The composite Innovation Score of 61.5/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 146 grants, compared with 158 in the 2015–2019 window — a -8% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. PACIFIC BIOSCIENCES OF CALIFORNIA, INC.'s 20.4 average claims per patent reflects complex, broadly scoped inventions that are difficult for competitors to design around, while a multi-domain presence across 46 subclasses balances depth with breadth. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark PACIFIC BIOSCIENCES OF CALIFORNIA, INC. against peers pursuing similar technology classes.